Clinical trials: Insufficient Metabolic Control
Type 2 Diabetes Mellitus
Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on diet and exercise alone.
- Trial name
- NCT00736879
- Testing
- Dapagliflozin
- Where
- 62 sites in United States, Canada and 5 more
- Volunteers
- 497 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug…
- Trial name
- NCT01646320
- Testing
- Dapagliflozin, Saxagliptin, Metformin immediate release (IR)
- Where
- 66 sites in United States, Czechia and 6 more
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes who have never been treated with medication or have been taking…
- Trial name
- NCT00528372
- Testing
- Dapagliflozin, Metformin
- Where
- 78 sites in United States, Canada and 2 more
- Volunteers
- 1,067 people
- Sponsor
- AstraZeneca
Type 2 Diabetic Patients, Insufficient Metabolic Control
Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin
The aim of the study is to show that treatment with Glargine will lead to an improvement in beta cell function especially within times of maximal beta cell stress occurring after a meal.
- Conditions
- Type 2 Diabetic Patients, Insufficient Metabolic Control, OAD Treatment
- Trial name
- NCT00941148
- Testing
- Insulin Glargin, NPH insulin, Insulin detemir
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- ikfe-CRO GmbH
Diabetes Mellitus, Type 2
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (i.e.…
- Trial name
- NCT01106677
- Testing
- Canagliflozin, Sitagliptin, Metformin immediate release
- Where
- 125 sites in United States, Argentina and 20 more
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
The purpose of this study is to determine the long-term safety of the study intervention orforglipron as a monotherapy or in combination with oral antihyperglycemic medication.
- Trial name
- ACHIEVE-J (NCT06010004)
- Testing
- Orforglipron
- Where
- 40 sites in Japan
- Volunteers
- 401 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Saxagliptin Triple Oral Therapy
The purpose of this study is to determine whether the addition of saxagliptin to a patient's combination treatment of metformin and sulfonylurea for a 24 week period will provide better control of the patient's type 2 diabetes…
- Trial name
- NCT01128153
- Testing
- Saxagliptin
- Where
- 33 sites in Australia, Canada and 4 more
- Volunteers
- 257 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
Study D5553C00002 is a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 3 study to compare the safety and efficacy of exenatide once weekly (EQW) added to titrated basal insulin glargine with or…
- Trial name
- NCT02229383
- Testing
- Exenatide
- Where
- 123 sites in United States, Hungary and 4 more
- Volunteers
- 464 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Familial Hypercholesterolemia
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)
The study will assess the safety and tolerability of Ezetimibe 10 mg+ Rosuvastatin 2.5 mg and Ezetimibe 10 mg+ Rosuvastatin 5.0 mg for up to 52 weeks in Japanese participants with hypercholesterolemia uncontrolled with…
- Trial name
- NCT02748057
- Testing
- Ezetimibe, Rosuvastatin
- Volunteers
- 135 people
- Sponsor
- Organon and Co
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.
- Trial name
- NCT00660907
- Testing
- dapagliflozin, glipizide, metformin hydrochloride
- Where
- 76 sites in Argentina, France and 8 more
- Volunteers
- 1,217 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)
This study assessed the safety and efficacy of MK-3577. The primary efficacy hypothesis was that, after 4 weeks of treatment, either the morning (AM) administration or the evening (PM) administration of MK-3577 provides superior…
- Trial name
- NCT00868790
- Testing
- MK-3577, Metformin
- Volunteers
- 118 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Non-Insulin-Dependent
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
- Trial name
- NCT00411554
- Testing
- sitagliptin phosphate, Comparator: voglibose
- Volunteers
- 319 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61…
- Trial name
- ACHIEVE-3 (NCT06045221)
- Testing
- Orforglipron, Semaglutide
- Where
- 131 sites in United States, Argentina and 4 more
- Volunteers
- 1,698 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Cardiovascular Disease
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
This study is carried out to assess whether dapagliflozin lowers blood glucose, body weight and blood pressure, when added to patients existing medications and how it compares with their usual treatment without added…
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control
- Trial name
- NCT01031680
- Testing
- Dapagliflozin
- Where
- 140 sites in United States, Argentina and 7 more
- Volunteers
- 922 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)
The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking metformin for type 2 diabetes.
- Trial name
- NCT00792935
- Testing
- MK-0941, Glimepiride, Metformin
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus Non-insulin-dependent
The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)
to assess the effect of treatment with Sitagliptin (MK0431) on HbA1c (Hemoglobin A1c) and the safety and tolerability of Sitagliptin.
- Trial name
- NCT00832624
- Testing
- sitagliptin
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes
- Trial name
- NCT00313313
- Testing
- Saxagliptin, Glyburide, Metformin
- Where
- 115 sites in United States, Argentina and 11 more
- Volunteers
- 768 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)
A study of patients with type 2 diabetes and inadequate glycemic control on two or more oral antihyperglycemic agents comparing adding insulin lispro mid mixture to the oral antihyperglycemic agents to adding insulin glargine to…
- Trial name
- IOOX (NCT00377858)
- Testing
- Insulin lispro mid mixture (MM), Insulin glargine
- Where
- 25 sites in Australia, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg + linagliptin.
- Trial name
- NCT02489968
- Testing
- empagliflozin 10 mg + linagliptin 5 mg, empagliflozin 10 mg, empagliflozin 25 mg + linagliptin 5 mg
- Where
- 83 sites in Japan
- Volunteers
- 880 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
This trial will evaluate the efficacy and safety of ertugliflozin monotherapy in the treatment of participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on diet and exercise.
- Trial name
- NCT01958671
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg, Metformin
- Volunteers
- 461 people
- Sponsor
- Merck Sharp & Dohme LLC